$2.480
+0.367 (+14.81%)Al cierre
Comparativa sectorial de XRTX
In the context of the broader market, XRTX competes directly with industry leaders such as GELS and PCSA. With a market capitalization of $4.51M, it holds a significant position in the sector. When comparing efficiency, XRTX's gross margin of N/A stands against GELS's N/A and PCSA's N/A. Such benchmarking helps identify whether XORTX Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Desempeño financiero de XORTX Therapeutics Inc
XORTX has shown mixed financial performance, with a recent net income of -808472 USD in Q1 2026 and a forward P/E of 0.9621, suggesting potential for recovery but also indicating ongoing losses.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.